Kyowa Kirin ha reafirmado su compromiso con el desarrollo de rocatinlimab como un activo diferenciado para tratar la dermatitis atópica de moderada a grave. La presentación regulatoria está programada para el primer semestre de 2026. La compañía ha completado su colaboración con Amgen y recuperará el control global del programa de rocatinlimab. Resultados de estudios de fase 3 publicados en The Lancet demostraron la eficacia de rocatinlimab. El medicamento, un anticuerpo monoclonal anti-OX40, muestra potencial para ofrecer un control duradero de la enfermedad en pacientes. Kyowa Kirin planea solicitar aprobación regulatoria en Estados Unidos y Japón. Kyowa Kirin reiterates its commitment to developing roctanlimab as a differentiated asset with transformative potential and significant market potential. The innovative approach of roctanlimab, as an investigational T cell rebalancing therapy that directly targets the OX40 receptor expressed on pathogenic T cells, has the potential to provide lasting disease control in patients with moderate to severe atopic dermatitis (msAD). Regulatory submission is planned for the first half of 2026. A shared commitment to our values, sustainable growth, and the purpose of making people smile unites us worldwide. Contact Kyowa Kirin for more information.

Read more at GlobeNewswire

Kyowa Kirin reiterates commitment to developing roctinlimab as a differentiated asset with transformative potential and significant market opportunity. Roctinlimab’s innovative approach as an investigational T cell rebalancing therapy targeting the OX40 receptor expressed on pathogenic T cells shows potential for providing long-lasting disease control in patients with moderate to severe atopic dermatitis (msAD). Regulatory submission is expected in the first half of 2026.: Kyowa Kirin recupera el control del programa de desarrollo